Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Badrising SK, van der Noort V, van den Eertwegh AJ, Hamberg P, van Oort IM, van den Berg HP, Los M, Aarts MJ, Coenen JL, Gelderblom H, de Jong IJ, Kerver ED, Vrijaldenhoven S, van Voorthuizen T, Warmerdam F, Haanen JB, Bergman AM; Dutch Uro-Oncology Studygroup.
Badrising SK, et al. Among authors: van den berg hp.
Prostate. 2016 Jan;76(1):32-40. doi: 10.1002/pros.23094. Epub 2015 Sep 22.
Prostate. 2016.
PMID: 26390914